3145P A phase II study of participant (pt)-reported preference for pembrolizumab (pembro) administered subcutaneously (SC) or intravenously (IV)
Makaleler > Tam Makale · 2025
Yazarlar: I.A. Casarini, D.M. Kowalski, C. Caglevic, S.B. Karaca Yayla, A.T. Sumbul, P.E. Yanez Weber, A.N. Yanzi Castilla, O. Bylicki, T. Takagi, K. McQuarrie, S. Saraf, A. Arunachalam, N. Bhagwati, G.L. Cohen
Annals of Oncology, Uluslararası, Wos, 2025, cilt 36, ss S637-S637